FLX Bio, Inc. is an immuno-oncology company focused on the discovery and development of orally-available, small molecule drug ... s to activate the immune system and eradicate cancer. Using its integrated immuno-oncology drug discovery platform, FLX Bio’s small molecule compounds specifically target proteins and pathways important for regulatory T cells or myeloid cells within the tumor microenvironment. Its lead candidate FLX475, a best-in-class CCR4 inhibitor, entered Phase 1 studies in December 2017 and has the potential to be used alone or in combination with checkpoint inhibitors to treat a variety of cancers. The company employs a precision medicine strategy for prospective patient selection in clinical studies, applying its robust computational and translational biology capabilities to identify key biomarkers that should maximize clinical response and increase the probability of clinical success. In addition, FLX is developing small molecule inhibitors of GCN2, a stress response kinase that detects amino acid starvation in the tumor microenvironment, and USP7, a therapeutic target involved in multiple cancer pathways. Located in South San Francisco, Calif., and funded by leading investors, including The Column Group (TCG), Kleiner Perkins (KP), Topspin Partners, GV (formerly Google Ventures) and Celgene Corporation, FLX Bio has assembled a leadership team and advisory group with a proven track record of success and team of scientists with substantial knowledge and expertise in drug discovery and translational areas essential to execute on this approach. For more information, please visit www.flxbio.com. read more